Chemotherapy was administered to 53 patients with hydatid disease; to 27 of them it was administered to prevent recurrences. Mebendazole was prescribed by courses lasting for 14 to 30 days with intervals between the courses of 1 to 3 months, in a daily dose of 50 mg/kg to be taken 4 times. The treatment efficacy was assessed in accordance with the criteria suggested by the WHO experts. On the whole our results did not evidence any essential differences in mebendazole therapy efficacy in our patients and in those represented in a WHO report. No recurrences occurred over the period of observation, that lasted for 6 months to 6 years, in the 27 patients who were administered the drug to prevent the disease recurrences. The treatment was fairly effective in 27% of the patients, good effect was attained in 42%, no desirable results were attained in 19%, and lethal outcomes were recorded in 12% of patients.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients hydatid
8
patients
6
[the efficacy
4
efficacy mebendazole
4
mebendazole treatment
4
treatment patients
4
hydatid disease]
4
disease] chemotherapy
4
chemotherapy administered
4
administered patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!